Janux Therapeutics (JANX) Total Current Liabilities (2020 - 2026)

Janux Therapeutics (JANX) has reported Total Current Liabilities for 7 consecutive years, with $58.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities rose 236.62% year-over-year to $58.9 million; the TTM figure through Mar 2026 stood at $58.9 million (up 236.62% YoY), while the FY2025 annual figure was $25.0 million, up 43.18% from the prior year.
• Total Current Liabilities climbed to $58.9 million in Q1 2026 per JANX's latest filing, from $25.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $58.9 million in Q1 2026 and bottomed at $10.6 million in Q1 2024.
• Historically, Total Current Liabilities has averaged $19.3 million across 5 years, with a median of $16.5 million in 2022.
• Annual changes were most pronounced in 2024 — Total Current Liabilities plunged 35.52% — and 2026, when it jumped 236.62%.
• Janux Therapeutics' Total Current Liabilities stood at $16.5 million in 2022, then decreased by 21.05% to $13.0 million in 2023, then jumped by 33.96% to $17.5 million in 2024, then jumped by 43.18% to $25.0 million in 2025, then soared by 135.69% to $58.9 million in 2026.
• Business Quant data shows JANX's Total Current Liabilities at $58.9 million in Q1 2026, $25.0 million in Q4 2025, and $27.8 million in Q3 2025.